Atopic Dermatitis (AD) Treatment Market By Drug Type (Anti-Inflammatory Agents, Antihistamines, Immunomodulators, Interleukin Inhibitors, Topical Phosphodiesterase-4 (PDE-4) Inhibitors, Antiviral Agents, Antibiotics) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Published By: Brisk Insights | Published On: Apr 11, 2022

 

Atopic dermatitis is also known as atopic eczema, it is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Atopic Dermatitis treatment market is rapidly growing due to factors such as growing prevalence of AD, significant unmet needs, promising pipeline molecules would fuel the market growth of atopic dermatitis treatment.

 

The report titled “Atopic Dermatitis (AD) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall Atopic Dermatitis (AD) treatment market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug type and different geographical regions. Geographically, the global AD treatment market is studied for the following regional markets:

 

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of MEA

 

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

 

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global AD treatment market. Pipeline analysis of AD treatment molecule and global epidemiology data have been included in report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global AD treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global AD treatment market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.     

 

Thus, the research study provides a holistic view of the global AD treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

 

Based on drug type, the global atopic dermatitis (AD) treatment market is segmented as follows:

 

  • Anti-inflammatory agents 
    • Corticosteroids
    • Calcineurin Inhibitors
  • Antihistamines
  • Immunomodulators
  • Interleukin Inhibitors
  • Topical Phosphodiesterase-4 (PDE-4) Inhibitors
  • Antiviral agents
  • Antibiotics

 

Atopic dermatitis (AD) also referred as atopic eczema, is an inflammatory disease of the skin, in which the skin becomes extremely itchy and inflamed, causing redness, swelling, vesicle formation. There is no cure for AD but medications are used to relief itching and prevent new outbreaks. It is studied that, currently anti-inflammatory agents held largest market share in global atopic dermatitis treatment market. Among considered anti-inflammatory segment corticosteroids is major revenue generating segment as these are preferred as first line treatment after failure of skin care and moisturizers due to its effectiveness. It is estimated that new product launch would drive the AD treatment market growth during forecast period. Pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab and tralokinumab are expected to show AD treatment market growth during forecast period. However, adverse effects associated with medication and poor treatment compliance in some countries may negatively impacting AD treatment market growth.

 

For the purpose of this study, the global atopic dermatitis (AD) treatment market is categorized into:

 

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

 

Atopic dermatitis (AD) is a chronic, inflammatory disease of the skin characterized by dry, itchy skin. The prevalence of AD is approximately 15 - 20% in children and 1-3% of adults worldwide and the incidence has increased by 2 to 3 folds during the past decades in industrialized countries. Among the considered geographical segment, North America was major revenue generating segment in the base year 2016. Some factors such as increase in prevalence of AD, higher treatment awareness, swift adoption of novel medications, better reimbursement policies in healthcare systems are the prime contributors of the dominance in North America Atopic dermatitis market. Expenditure on healthcare is highest in the United States as compared to other nations is another factor contributing growth of AD treatment market. According to American Academy of Dermatology approximately 10 to 20 percent of childrens in the United States develop atopic dermatitis; AD affects more than 28 million people of all ages in the United States alone. It is estimated that, Asia Pacific will show highest AD treatment market growth during forecast period due to increasing healthcare awareness among general patient population, developing economic conditions, growing number of investment and partnering of key player with local manufacturers.

 

Chapter 1 Preface


1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

 

Chapter 2 Executive Summary


2.1 Global Atopic Dermatitis (AD) Treatment Market Snapshot
2.2 Global Atopic Dermatitis (AD) Treatment Market, by Drug Type
2.3 Global Atopic Dermatitis (AD) Treatment Market Share, by Geography, 2016 (Value %)

 

Chapter 3 Atopic Dermatitis (AD) Treatment Market Analysis


3.1 Global Atopic Dermatitis (AD) Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Atopic Dermatitis (AD) Treatment Drugs
3.4 Global Epidemiology of Atopic Dermatitis (AD)
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Atopic Dermatitis (AD) Treatment Market

 

Chapter 4 Global Atopic Dermatitis (AD) Treatment Market, by Drug Type


4.1 Overview
4.2 Attractive Investment Proposition: Global Atopic Dermatitis (AD) Treatment Market, by Drug Type
4.3 Top 3 Countries
4.4 Anti-inflammatory agents
4.4.1 Corticosteroids
4.4.2 Calcineurin Inhibitors
4.5 Antihistamines
4.6 Immunomodulators
4.7 Interleukin Inhibitors
4.8 Topical Phosphodiesterase-4 (PDE-4) Inhibitors
4.9 Antiviral agents
4.10 Antibiotics

 

Chapter 5 Global Atopic Dermatitis (AD) Treatment Market, By Geography


5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.2.2 North America Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.3.2 Europe Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.5.2 Latin America Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)

 

Chapter 6 Company Profiles


6.1 AbbieVie Inc.
6.2 Encore Dermatology Inc.
6.3 F. Hoffmann-La Roche AG
6.4 Glaxosmithkline plc.
6.5 LEO Pharma A/S
6.6 Medimmune LLC. (Astrazeneca)
6.7 Novartis AG
6.8 Pfizer Inc.
6.9 Regeneron Pharmaceuticals Inc.
6.10 Sanofi S.A.
6.11 Valeant Pharmaceuticals Inc.

TABLE 1 Market Positioning of Key Players in Global Atopic Dermatitis (AD) Treatment Market
TABLE 2 Global Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015 – 2025 (US$ Bn)
TABLE 3 Top 3 Countries in Global Atopic Dermatitis (AD) Treatment Market, 2015 – 2025 (US$ Bn)
TABLE 4 Global Anti-inflammatory agents in Atopic Dermatitis (AD) Treatment, 2015 – 2025 (US$ Bn)
TABLE 5 Global Atopic Dermatitis (AD) Treatment Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 6 North America Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 7 North America Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 8 Europe Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 9 Europe Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 10 Asia Pacific Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 11 Asia Pacific Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 12 Latin America Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 13 Latin America Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 14 Middle East and Africa Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 15 Middle East and Africa Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 16 AbbieVie Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 17 Encore Dermatology Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 18 F. Hoffmann-La Roche AG: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 19 Glaxosmithkline plc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 20 LEO Pharma A/S: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 21 Medimmune LLC. (Astrazeneca): Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 22 Novartis AG: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 23 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 24 Regeneron Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 25 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 26 Valeant Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)

FIG. 1 Atopic Dermatitis (AD) Treatment Market: Research Methodology
FIG. 2 Global Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2016 (US$ Bn)
FIG. 3 Global Atopic Dermatitis (AD) Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Atopic Dermatitis (AD) Treatment Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Atopic Dermatitis (AD) Treatment Market, by Drug type, 2016
FIG. 6 Global Corticosteroids Market, 2015 – 2025 (US$ Bn)
FIG. 7 Global Calcineurin Inhibitors Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Antihistamines Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Immunomodulators Market, 2015 – 2025 (US$ Bn)
FIG. 10 Global Interleukin Inhibitors Market, 2015 – 2025 (US$ Bn)
FIG. 11 Global Topical Phosphodiesterase-4 (PDE-4) Inhibitors Market, 2015 – 2025 (US$ Bn)
FIG. 12 Global Antiviral agents Market, 2015 – 2025 (US$ Bn)
FIG. 13 Global Antibiotics Market, 2015 – 2025 (US$ Bn)

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)